S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
NASDAQ:CARA

Cara Therapeutics Stock Forecast, Price & News

$11.95
+0.30 (+2.58%)
(As of 01/14/2022 12:00 AM ET)
Add
Compare
Today's Range
$11.58
$11.99
50-Day Range
$11.65
$18.14
52-Week Range
$11.22
$29.65
Volume
307,424 shs
Average Volume
367,030 shs
Market Capitalization
$638.84 million
P/E Ratio
24.39
Dividend Yield
N/A
Beta
1.06
30 days | 90 days | 365 days | Advanced Chart
Receive CARA News and Ratings via Email

Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Cara Therapeutics logo

About Cara Therapeutics

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Headlines

Cara Therapeutics: Bullish on FDA Approval
November 12, 2021 |  nasdaq.com
Cara Therapeutics earnings: here's what to expect
November 7, 2021 |  markets.businessinsider.com
Cara Therapeutics Announces CEO Transition
November 3, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CARA
Employees
80
Year Founded
N/A

Sales & Book Value

Annual Sales
$135.08 million
Cash Flow
$0.19 per share
Book Value
$5.00 per share

Profitability

Net Income
$8.41 million
Pretax Margin
17.57%

Debt

Price-To-Earnings

Miscellaneous

Free Float
50,145,000
Market Cap
$638.84 million
Optionable
Optionable

Company Calendar

Last Earnings
11/07/2021
Today
1/17/2022
Next Earnings (Estimated)
2/24/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.29 out of 5 stars

Medical Sector

289th out of 1,405 stocks

Pharmaceutical Preparations Industry

129th out of 678 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions

Is Cara Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cara Therapeutics stock.
View analyst ratings for Cara Therapeutics
or view top-rated stocks.

How has Cara Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Cara Therapeutics' stock was trading at $13.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CARA shares have decreased by 11.0% and is now trading at $11.95.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Cara Therapeutics?

Cara Therapeutics saw a decrease in short interest during the month of December. As of December 15th, there was short interest totaling 2,070,000 shares, a decrease of 19.8% from the November 30th total of 2,580,000 shares. Based on an average daily volume of 671,200 shares, the short-interest ratio is currently 3.1 days. Currently, 4.7% of the company's stock are sold short.
View Cara Therapeutics' Short Interest
.

When is Cara Therapeutics' next earnings date?

Cara Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Cara Therapeutics
.

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) released its quarterly earnings data on Sunday, November, 7th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.36) by $0.34. The biopharmaceutical company earned $20.27 million during the quarter, compared to analyst estimates of $15.74 million. During the same period last year, the business posted ($0.35) earnings per share.
View Cara Therapeutics' earnings history
.

What price target have analysts set for CARA?

3 brokerages have issued 12-month price targets for Cara Therapeutics' stock. Their forecasts range from $16.00 to $35.00. On average, they expect Cara Therapeutics' stock price to reach $25.67 in the next twelve months. This suggests a possible upside of 114.8% from the stock's current price.
View analysts' price targets for Cara Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Cara Therapeutics' key executives?

Cara Therapeutics' management team includes the following people:

What other stocks do shareholders of Cara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), (CGC), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), (XXII), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY).

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Patriot Financial Group Insurance Agency LLC (0.08%) and Baldwin Brothers LLC MA (0.02%). Company insiders that own Cara Therapeutics stock include Christopher Posner, Derek T Chalmers, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion and Thomas Charles Reilly.
View institutional ownership trends for Cara Therapeutics
.

Which major investors are selling Cara Therapeutics stock?

CARA stock was sold by a variety of institutional investors in the last quarter, including Baldwin Brothers LLC MA. Company insiders that have sold Cara Therapeutics company stock in the last year include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion, and Thomas Charles Reilly.
View insider buying and selling activity for Cara Therapeutics
or view top insider-selling stocks.

Which major investors are buying Cara Therapeutics stock?

CARA stock was acquired by a variety of institutional investors in the last quarter, including Patriot Financial Group Insurance Agency LLC.
View insider buying and selling activity for Cara Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Cara Therapeutics?

Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cara Therapeutics' stock price today?

One share of CARA stock can currently be purchased for approximately $11.95.

How much money does Cara Therapeutics make?

Cara Therapeutics has a market capitalization of $638.84 million and generates $135.08 million in revenue each year. The biopharmaceutical company earns $8.41 million in net income (profit) each year or $0.49 on an earnings per share basis.

How many employees does Cara Therapeutics have?

Cara Therapeutics employs 80 workers across the globe.

What is Cara Therapeutics' official website?

The official website for Cara Therapeutics is www.caratherapeutics.com.

Where are Cara Therapeutics' headquarters?

Cara Therapeutics is headquartered at 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902.

How can I contact Cara Therapeutics?

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at (203) 406-3700, via email at [email protected], or via fax at 203-567-1510.


This page was last updated on 1/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.